Adaptive patient enrichment designs in therapeutic trials
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The utility of clinical trial designs with adaptive patient enrichment is investigated in an adequate and well‐controlled trial setting. The overall treatment effect is the weighted average of the treatment effects in the mutually exclusive subsets of the originally intended entire study population. The adaptive enrichment approaches permit assessment of treatment effect that may be applicable to specific nested patient (sub)sets due to heterogeneous patient characteristics and/or differential response to treatment, e.g. a responsive patient subset versus a lack of beneficial patient subset, in all patient (sub)sets studied. The adaptive enrichment approaches considered include three adaptive design scenarios: (i) total sample size fixed and with futility stopping, (ii) sample size adaptation and futility stopping, and (iii) sample size adaptation without futility stopping. We show that regardless of whether the treatment effect eventually assessed is applicable to the originally studied patient population or only to the nested patient subsets; it is possible to devise an adaptive enrichment approach that statistically outperforms one‐size‐fits‐all fixed design approach and the fixed design with a pre‐specified multiple test procedure. We emphasize the need of additional studies to replicate the finding of a treatment effect in an enriched patient subset. The replication studies are likely to need fewer number of patients because of an identified treatment effect size that is larger than the diluted overall effect size. The adaptive designs, when applicable, are along the line of efficiency consideration in a drug development program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423 · cited 1×
“One can use p-value combination tests, combining data from both stages in the closed test procedure (Marcus, Peritz, and Gabriel, 1976) applied to all relevant null hypotheses.”
MethodEvaluation of Experiments with Adaptive Interim Analyses
Bauer, P., & Kohne, K. (1994) · Biometrics · doi:10.2307/2533441 · Cited by 865 · cited 1×
“Irrespective of the enrichment adaptation rules, such a p-value combination test ensures the strong control of type I error (Bauer and Köhne, 1994; Bauer and Kieser, 1999; Hommel, 2001; Bretz et al., 2006).”
MethodModification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574
Self-citationClinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499 · cited 1×
“For prognostic, predictive, or prognostic–predictive utility of baseline characteristics known as (genomic) biomarkers that is used to select patients prior to treatment initiation, readers are referred to Sargent et al. (2005), Wang et al. (2007b), Wang (2007), and those references therein.”
BackgroundMonitoring clinical trials: Conditional or predictive power?
Spiegelhalter, D. J., Freedman, L. S., & Blackburn, P. R. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90003-6 · Cited by 307 · cited 1×
“The assessment can be based on the evaluation of the predictive power (Spiegelhalter, Freedman, and Blackburn, 1986; Proschan, Lan, and Wittes, 2006) or conditional power (CP) (Halperin et al., 1982).”
BackgroundCombining different phases in the development of medical treatments within a single trial
Bauer, P., & Kieser, M. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990730)18:14<1833::aid-sim221>3.0.co;2-3 · Cited by 287 · cited 1×
“Irrespective of the enrichment adaptation rules, such a p-value combination test ensures the strong control of type I error (Bauer and Köhne, 1994; Bauer and Kieser, 1999; Hommel, 2001; Bretz et al., 2006).”
MethodBretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006) · Biometrical Journal · doi:10.1002/bimj.200510232 · Cited by 272 · cited 1×
“Irrespective of the enrichment adaptation rules, such a p-value combination test ensures the strong control of type I error (Bauer and Köhne, 1994; Bauer and Kieser, 1999; Hommel, 2001; Bretz et al., 2006).”
MethodApproaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Wang, S., O'Neill, R. T., & Hung, H. M. J. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.300 · Cited by 263 · cited 2×
“Wang et al. (2007b) and Wang (2008) presented a lack of power phenomenon with a single-level adaptive enrichment when the classifier is only prognostic of treatment effect.”
BackgroundSelf-citationTanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J., & Bergh, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9264 · Cited by 251 · cited 1×
“There is clinical interest to investigate whether the TOP2A gene alone or co-amplification of HER2/neu would be more predictive than HER2/neu gene alone to the effect of anthracyclinebased adjuvant chemotherapy (Tanner et al., 2006).”
BackgroundAn aid to data monitoring in long-term clinical trials
Halperin, M., Gordon Lan, K. K., Ware, J. H., Johnson, N. J., & DeMets, D. L. (1982) · Controlled Clinical Trials · doi:10.1016/0197-2456(82)90022-8 · Cited by 195 · cited 1×
“The assessment can be based on the evaluation of the predictive power (Spiegelhalter, Freedman, and Blackburn, 1986; Proschan, Lan, and Wittes, 2006) or conditional power (CP) (Halperin et al., 1982).”
BackgroundCharacterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen, T. A. H., Tanner, M., Barlund, M. T., Borg, Å., & Isola, J. J. (1999) · PubMed · Cited by 188
Statistical Monitoring of Clinical Trials: a Unified Approach
Chernick, M. R. (2007) · Technometrics · doi:10.1198/tech.2007.s479 · Cited by 186 · cited 1×
“The assessment can be based on the evaluation of the predictive power (Spiegelhalter, Freedman, and Blackburn, 1986; Proschan, Lan, and Wittes, 2006) or conditional power (CP) (Halperin et al., 1982).”
BackgroundThe relationship between prognostic and predictive factors in the management of breast cancer
Henderson, I. C., & Patek, A. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006141703224 · Cited by 184
Baselga, J. (2001) · Oncology · doi:10.1159/000055397 · Cited by 180 · cited 1×
“6 Example Herceptin has been shown effective in patients with metastatic breast cancer whose tumors overexpress HER2 protein [Baselga, 2001].”
BackgroundAdaptive Modifications of Hypotheses After an Interim Analysis
Hommel, G. (2001) · Biometrical Journal · doi:10.1002/1521-4036(200109)43:5<581::aid-bimj581>3.0.co;2-j · Cited by 170 · cited 2×
“Irrespective of the enrichment adaptation rules, such a p-value combination test ensures the strong control of type I error (Bauer and Köhne, 1994; Bauer and Kieser, 1999; Hommel, 2001; Bretz et al., 2006).”
MethodUse of genomic signatures in therapeutics development in oncology and other diseases
Simon, R., & Wang, S.-J. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500349 · Cited by 143 · cited 2×
“For simplicity, assume that each covariate is dichotomized, such as age, gender, race, cancer stage, ECOG performance status (ECOG5 0 versus 40), baseline pain intensity (mild/moderate versus severe), genomic (composite) biomarker (positive versus negative or present versus absent) [Wang, 2006], and genomic signature…”
BackgroundSelf-citationKarlin, S., & Rinott, Y. (1981) · The Annals of Statistics · doi:10.1214/aos/1176345583 · Cited by 120 · cited 2×
“In the situation of testing three populations with the nested relationship r 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com described in Section 2, applying the Hochberg procedure may also achieve strong control of the family-wise type I error rate [see Huang and Hsu, 2007], provided that…”
Hochberg's Step-Up Method: Cutting Corners Off Holm's Step-Down Method
Huang, Y., & Hsu, J. C. (2007) · Biometrika · doi:10.1093/biomet/asm067 · Cited by 111 · cited 1×
“…in Section 2, applying the Hochberg procedure may also achieve strong control of the family-wise type I error rate [see Huang and Hsu, 2007], provided that the variances in all patient sets are equal and hence the correlation matrix of the three Z-tests satisfies MTP2…”
MethodThe reassessment of trial perspectives from interim data—a critical view
Bauer, P., & Koenig, F. (2006) · Statistics in Medicine · doi:10.1002/sim.2180 · Cited by 109
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI
Wang, S. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.316 · Cited by 35 · cited 1×
“For prognostic, predictive, or prognostic–predictive utility of baseline characteristics known as (genomic) biomarkers that is used to select patients prior to treatment initiation, readers are referred to Sargent et al. (2005), Wang et al. (2007b), Wang (2007), and those references therein.”
BackgroundSelf-citation
Cited by
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
“An extension known as adaptive enrichment designs fulfills the desire to target therapies to patients who can benefit the most from the treatment [38,39].”
Background
Metadata
- Authors
- Wang, S., James Hung, H. M., & O'Neill, R. T.
- Venue
- Biometrical Journal
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 51
- Issue
- 2
- Pages
- 358-374
- ISSN
- 0323-3847 (ISSN-L)
- 1521-4036
- OpenAlex
- W2000072919
- Cited by
- 158
- References
- 21
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.